{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:31:13Z","timestamp":1791397873130,"version":"4.3.3"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jaad.2013.05.019","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T05:00:31Z","timestamp":1374123631000},"page":"570-577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Cathelicidin, kallikrein 5, and serine protease activity\u00a0is inhibited during treatment of rosacea with azelaic acid 15% gel"],"prefix":"10.1016","volume":"69","author":[{"given":"Alvin B.","family":"Coda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tissa","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Audish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kotol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Two","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.05.019_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2004.03.033","article-title":"Rosacea, II: therapy","volume":"51","author":"Pelle","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib2","first-page":"531","article-title":"American Acne and Rosacea Society rosacea medical management guidelines","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib3","first-page":"97","article-title":"Standard management options for rosacea, part 2: options according to subtype","volume":"84","author":"Odom","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.05.019_bib4","first-page":"673","article-title":"Rosacea: a review of current topical, systemic and light-based therapies","volume":"144","author":"Kennedy Carney","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.05.019_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2013.05.019_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/1380-2933(95)00006-2","article-title":"Anti-microbial activity of human CAP18 peptides","volume":"1","author":"Larrick","year":"1995","journal-title":"Immunotechnology"},{"key":"10.1016\/j.jaad.2013.05.019_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1172\/JCI17545","article-title":"An angiogenic role for the human peptide antibiotic LL-37\/hCAP-18","volume":"111","author":"Koczulla","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2013.05.019_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1523-1747.2001.01340.x","article-title":"Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus","volume":"117","author":"Dorschner","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","article-title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2013.05.019_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/jid.2010.351","article-title":"TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes","volume":"131","author":"Yamasaki","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2133.2011.10473.x","article-title":"Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review","volume":"165","author":"van Zuuren","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib12","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1517\/14656566.9.15.2699","article-title":"Azelaic acid 15% gel in the treatment of rosacea","volume":"9","author":"Gollnick","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2013.05.019_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","article-title":"The effect of azithromycin on reactive oxygen species in rosacea","volume":"32","author":"Bakar","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib15","unstructured":"NIST\/SEMATECH e-Handbook of statistical methods. Available at: http:\/\/www.itl.nist.gov\/div898\/handbook\/. Accessed April 2012."},{"key":"10.1016\/j.jaad.2013.05.019_bib16","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","article-title":"Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin","volume":"132","author":"Kanada","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.019_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/jidsymp.2011.4","article-title":"Rosacea as a disease of cathelicidins and skin innate immunity","volume":"15","author":"Yamasaki","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2013.05.019_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1172\/JCI30142","article-title":"Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism","volume":"117","author":"Schauber","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2013.05.019_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.sder.2008.04.002","article-title":"Antimicrobial peptides, skin infections, and atopic dermatitis","volume":"27","author":"Hata","year":"2008","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2013.05.019_bib20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI28422","article-title":"Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor","volume":"116","author":"Sorensen","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2013.05.019_bib21","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1016\/j.jaci.2009.07.014","article-title":"Antimicrobial peptides and the skin immune defense system","volume":"124","author":"Schauber","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.019_bib22","doi-asserted-by":"crossref","first-page":"15258","DOI":"10.1074\/jbc.272.24.15258","article-title":"The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders","volume":"272","author":"Frohm","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2013.05.019_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2567.2006.02399.x","article-title":"Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli","volume":"118","author":"Schauber","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.jaad.2013.05.019_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15569527.2010.517230","article-title":"Why minimally invasive skin sampling techniques? A bright scientific future","volume":"30","author":"Wang","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jaad.2013.05.019_bib25","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood.V97.12.3951","article-title":"Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3","volume":"97","author":"Sorensen","year":"2001","journal-title":"Blood"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213005367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213005367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:27:01Z","timestamp":1759271221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213005367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0190962213005367"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.05.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cathelicidin, kallikrein 5, and serine protease activity\u00a0is inhibited during treatment of rosacea with azelaic acid 15% gel","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}